Abstract
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 result from formation of a fusion gene encoding an aberrant tyrosine kinase. The cell of origin in those neoplasms associated with abnormalities of PDGFRA or FGFR1 is a mutated pluripotent (i.e., myeloid-lymphoid) stem cell, and thus the development of myeloid and lymphoid neoplasms associated with these abnormalities. Reported neoplasms associated with abnormalities of PDGFRB have been only myeloid in origin. This review presents the definitions and characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features of these neoplasms and discusses in depth the differential diagnoses. Following this presentation, the review then focuses on therapeutic approaches, including targeted therapy.
Keywords: Myeloid neoplasms, lymphoid neoplasms, PDGFRA, PDGFRB, FGFR1
Current Cancer Therapy Reviews
Title: Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Volume: 8 Issue: 1
Author(s): Cherie H. Dunphy
Affiliation:
Keywords: Myeloid neoplasms, lymphoid neoplasms, PDGFRA, PDGFRB, FGFR1
Abstract: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 result from formation of a fusion gene encoding an aberrant tyrosine kinase. The cell of origin in those neoplasms associated with abnormalities of PDGFRA or FGFR1 is a mutated pluripotent (i.e., myeloid-lymphoid) stem cell, and thus the development of myeloid and lymphoid neoplasms associated with these abnormalities. Reported neoplasms associated with abnormalities of PDGFRB have been only myeloid in origin. This review presents the definitions and characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features of these neoplasms and discusses in depth the differential diagnoses. Following this presentation, the review then focuses on therapeutic approaches, including targeted therapy.
Export Options
About this article
Cite this article as:
H. Dunphy Cherie, Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462503
DOI https://dx.doi.org/10.2174/157339412799462503 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
(1→3)-α-D-Glucans from Aspergillus spp.: Structural Characterization and Biological Study on their Carboxymethylated Derivatives
Current Drug Targets Progress in the Development of Bestatin Analogues as Aminopeptidases Inhibitors
Current Medicinal Chemistry Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor – 3
Current Radiopharmaceuticals Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Current Topics in Medicinal Chemistry Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
Current Immunology Reviews (Discontinued) Stem Cell Defects in Philadelphia Chromosome Negative Chronic Myeloproliferative Disorders: A Phenotypic and Molecular Puzzle?
Current Stem Cell Research & Therapy Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Role of CHK2 Inhibitors in the Cellular Responses to Ionizing Radiation
Mini-Reviews in Medicinal Chemistry Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry The Novel Role for Lyn in Integrin Signaling in Human Disease
Current Signal Transduction Therapy The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry New Molecules and Strategies in the Field of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents A Facile “Click Chemistry” Approach to Novel Flavonol Glycoconjugates and Their Cytotoxic Activity
Letters in Organic Chemistry Engineered Peptides for Applications in Cancer-Targeted Drug Delivery and Tumor Detection
Mini-Reviews in Medicinal Chemistry Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives
Current Pharmaceutical Biotechnology